search

Active clinical trials for "Dermatitis, Atopic"

Results 141-150 of 1075

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Moderate-to-Severe Atopic Dermatitis

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description

Active10 enrollment criteria

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants...

Atopic Dermatitis

The objective of this study is to evaluate the safety, pharmacokinetics and tolerability of multiple doses of upadacitinib in pediatric participants with severe atopic dermatitis and to evaluate palatability of upadacitinib oral solution in pediatric participants.

Active8 enrollment criteria

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects...

DermatitisAtopic

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to severe atopic dermatitis and have completed a qualifying parent study. The efficacy and safety of two dosage strengths of Abrocitinib, 100 mg and 200 mg taken orally once daily, will be evaluated over variable lengths of study participation. The study consists of a 92 week initial treatment period followed by a variable length secondary treatment period during which subjects will receive treatment with open-label abrocitinib until availability of commercial product in their country, or until the sponsor terminates the study in that country. The B7451015 study also includes a sub-study evaluating whether abrocitinib has any potential effects on adolescent bone with regard to abnormal bone findings in knee MRI. The sub-study will be conducted in selected countries at selected sites. Eligible subjects are those who were 12 to <18 years of age at the screening visit of the qualifying parent study and who are currently participating in the main B7451015 study. The sub-study will include serial Magnetic Resonance Imaging (MRI) annually and continue until all enrolled subjects are 18 years of age and have been imaged at least once or have discontinued/withdrawn.

Active21 enrollment criteria

Study of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Atopic Dermatitis

Atopic Dermatitis

This study is to reflect the effectiveness and safety of MG-K10 humanized monoclonal antibody injection in patients with moderate to severe atopic dermatitis.

Active23 enrollment criteria

A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in...

Moderate-to-severe Atopic Dermatitis

This study will evaluate the efficacy and safety of CBP-201 in Chinese subjects with moderate to severe atopic dermatitis.

Active38 enrollment criteria

Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe...

Atopic Dermatitis

This 110-week study is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis.

Active38 enrollment criteria

A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe...

DermatitisAtopic

The purpose of this study is to assess the effect of nemolizumab (CD14152) on humoral immune responses to tetanus and meningococcal vaccination in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD).

Active11 enrollment criteria

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18...

Atopic Dermatitis

The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD. The secondary objectives of the study are: To assess the long-term efficacy of dupilumab in pediatric participants with AD To assess the trough concentrations of functional dupilumab in serum and the immunogenicity in pediatric participants with AD after re-treatment with dupilumab Optional Pre-filled Pen (PFP) Sub-Study in pediatric patients ≥2 to <12 years of age with AD Co-Primary Objectives are: To evaluate the pharmacokinetic (PK) of dupilumab PFPs To evaluate the safety of dupilumab PFPs Secondary Objective is: - To evaluate the immunogenicity of dupilumab PFPs

Active19 enrollment criteria

A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis

Atopic Dermatitis

The reason for this study is to see if the study drug called baricitinib works and is safe in children and teenage participants with atopic dermatitis.

Active23 enrollment criteria

Aquacel Hypersensitivity Dressing in TJAs

Contact Allergic DermatitisAdverse Skin Reaction

The aim of this multi-surgeon, single institution study is to prospectively evaluate the incidence of allergic contact dermatitis (ACD) following application of AQUACEL Ag, a silver-containing hydrofiber dressing, in total hip and knee arthroplasty patients. Arthroplasty-naïve patients will be compared to prior total joint arthroplasty patients who received a Aquacel dressing postoperatively.

Recruiting7 enrollment criteria
1...141516...108

Need Help? Contact our team!


We'll reach out to this number within 24 hrs